Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ridgway, G. L.
Right arrow Articles by Oriel, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ridgway, G. L.
Right arrow Articles by Oriel, J. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1983) 12, 511-514
© 1983 The British Society for Antimicrobial Chemotherapy

research-article

The activity of miokamycin (MOM) against Chlamydia trachomatis and mycoplasmas in vitro

Geoffrey L. Ridgway, Gilanfar Mumtaz, Guy Gabriel and J. David Oriel*

* Departments of Clinical Microbiology, University College Hospital London WCl, England Genito- Urinary Medicine, University College Hospital London WCl, England

accepted 27 May 1983

The activity of miokamycin, a new macrolide, was investigated against Chlamydia trachomatis, Ureaplasma urealyticum and Mycoplasma hominis, in vitro. Mioka-mycin was found to be similar in activity to doxycycline and erythromycin against Chlam. trachomatis and U. urealyticum. Against Mycopl, hominis, miokamycin had an activity clearly superior to erythromycin.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.